China National Medicines (SHA:600511) recorded a 13% year-over-year rise in attributable profit in the third quarter of 2025 to 543.7 million yuan, a Tuesday filing by parent Sinopharm (HKG:1099) said.

Basic EPS was 0.72 yuan in the three months, with revenue rising 3.6% to 13.7 billion yuan.

For the nine months ended Sept. 30, the drug maker's attributable profit and revenue increased 0.7% and 3.6%, respectively, to 1.49 billion yuan and 39.4 billion yuan.